In the proteomics cohort, MPO was increased in AF while metformin and statin use did not differ between patients with and without AF [20], and in the immunohistochemistry cohort, MPO was increased in future onset AF, while medication use, age, BMI, diabetes%, and LAVI did not differ between future onset and non-AF patients. The gene discussed is MPO; the disease is atrial fibrillation.